Previous Article | Next Article ![]()
Molecular and Cellular Biology, March 2002, p. 1926-1935, Vol. 22, No. 6
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.6.1926-1935.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Biotechnology and Biomedical Sciences,1 Department of Biology and Agro-Industrial Economics, University of Udine, I-33100 Udine,2 C.N.R. Center for the Study of Biomembranes at the Department of Biomedical Sciences, University of Padua, I-35121 Padua,3 Department of Biochemistry, Biophysics, and Chemistry of Macromolecules, University of Trieste, Trieste, Italy4
Received 22 May 2001/ Returned for modification 27 July 2001/ Accepted 13 November 2001
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The human antimicrobial peptide hystatin 5 was recently added to the number of toxic agents that act through mitochondria. This molecule is cytotoxic to Candida albicans in a manner dependent on functionally active mitochondria, as inhibition of respiration protects the cells from its toxicity (16). Likewise, de-energized human cell lines are protected from the cytotoxic effects of other antimicrobial peptides such as the human defensins (25, 26) and the bovine BMAP-28, a cationic peptide of the cathelicidin family (34, 36, 45). The latter agent causes membrane permeabilization and death of activated human lymphocytes and tumor cells (34). The cytotoxic activity has been related to the structural features of the peptide, which consists of a cationic N-terminal sequence predicted to assume an amphipathic
-helical conformation (residues 1 to 18) and a C-terminal hydrophobic tail (residues 19 to 27). The C-terminal sequence seems to be crucial for the cytotoxic activity, as a great reduction of this effect is observed with the synthetic analogue BMAP-28(1-18) comprising the 18 N-terminal residues (36). A second requirement for cytotoxicity is an active metabolism of the target cells, as BMAP-28 is ineffective in nonrespiring cells (34).
In view of these observations, we have investigated whether mitochondria are targets of the peptide itself and/or mediators of its cytotoxic effect. We show that BMAP-28 dramatically affects mitochondrial membrane permeability. Indeed, the peptide caused mitochondrial depolarization, permeabilization to calcein, and in situ cytochrome c release. These effects were detected at micromolar or even submicromolar concentrations of the full-length peptide but not detected in BMAP-28(1-18), were potentiated by Ca2+ ions, and were inhibited by cyclosporine (CsA), an inhibitor of the mitochondrial permeability transition pore (PTP) (4, 28). We conclude that perturbation of mitochondrial function and cytochrome c release are key events in the cytotoxicity of BMAP-28.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Mononuclear cells were isolated by Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation from peripheral blood of healthy donors. The cells were resuspended in RPMI 1640 medium supplemented with 10% FCS, 50 IU of penicillin/ml, 50 µg of streptomycin/ml, and 2 mM L-glutamine and were activated with 10 µg of phytohemagglutinin-P (PHA-P)/ml. After 2 days of culture in 25-cm2 cell culture flasks at 37°C in a CO2 incubator, the blasts were washed and seeded in 24-well plates at 6 x 105 cells/ml in culture medium containing 100 U of human recombinant interleukin-2 (hrIL-2; Genzyme, Cambridge, Mass.)/ml, and autologous adherent leukocytes were used as feeder cells.
Unless otherwise specified, all reagents and chemicals were from Sigma (St. Louis, Mo.). Safranin O, JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolcarbocyanine iodide), BAPTA-AM [1,2-bis (2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acetoxymethyl ester], and calcein-AM were purchased from Molecular Probes (Eugene, Oreg.), dissolved, and stored according to the manufacturer's instructions. 9-Fluorenylmethoxy carbonyl, amino acids, and reagents for peptide synthesis were obtained from PerSeptive Biosystems (Framingham, Mass.) and Novabiochem (Laufelflingen, Switzerland). Reagents for high-performance liquid chromatography purification of the peptides were from LabScan (Dublin, Ireland).
Peptide synthesis and purification. BMAP-28, a 28-residue peptide whose C-terminal glycine is removed to give a 27-residue amidated peptide (36), was synthesized as a C-terminal amide of 27 amino acids (GGLRSLGRKILRAWKKYGPIIVPIIRI-am). Solid-phase synthesis of this molecule, of the analogue BMAP-28(1-18) (GGLRSLGRKILRAWKKYG-am), and of the fragment corresponding to the fibronectin region (CS-5) (GEEIQIGHIPREDVDYHLYP) was carried out on a Milligen 9050 synthesizer (Bedford, Mass.). After cleavage from the resin, the peptides were purified by reverse-phase high-performance liquid chromatography on a C18 Delta-pack column (Waters, Bedford, Mass.). Analytical assays and determination of the concentration were performed as described in reference 36.
Determinations of changes of mitochondrial membrane potential in intact cells. U937 cells in complete medium (2 x 106 cells/ml) were stained with 5 µM JC-1 for 20 min at room temperature in the dark (9, 12), then washed in ice-cold phosphate-buffered saline solution (PBS), and incubated at a cell density of 4 x 106 cells/ml for 15 min at 37°C in PBS-5 mM glucose with the peptides or with FCCP [carbonylcyanide-p-(trifluoromethoxy)phenylhydrazone] for 45 min. Cells were analyzed immediately with a flow cytometer equipped with the Cell Quest software by using a 488-nm argon ion laser as the excitation source (FACScan; Becton Dickinson, Mansfield, Mass.). In a parallel experiment, the cells were treated with the peptides as described above and then stained with propidium iodide (10 µg/ml) and analyzed with the cytofluorimeter. The same procedure was used for K562 cells and activated lymphocytes, with the exception that the treatment of lymphocytes with BMAP-28 or FCCP was carried out in RPMI-10% FCS.
When indicated, 10 µM BAPTA-AM was added to the cell suspensions throughout the staining with JC-1 and the incubation with the peptides. In the experiments with CsA, the cells were stained with JC-1 as described above, then incubated with 10 µM CsA for 40 min at 37°C in RPMI-10% FCS, washed in PBS, and treated with BMAP-28 or with FCCP in the presence of CsA.
After 30 min of incubation, the peptide caused necrotic death and disruption of 30 to 35% of the cells, as determined by cytofluorimetric analysis of physical parameters (forward and side light scattering) and lactate dehydrogenase release assay of the cell culture supernatants (34). We therefore monitored the changes in 
m after a shorter incubation time (15 min), and we gated out dead cells and debris (25 to 30% of all cells) by analyzing the cells stained with propidium iodide on FSC (forward scatter) versus FL3 (propidium fluorescence). A gate set on the FSC-FL3 dot plot for each sample was used to include only viable cells in the analysis of the parallel cell population stained with JC-1. Cells (10,000 per sample) were examined on an FL-1 (530 nm) versus FL-2 (585 nm) dot plot, and the data were analyzed with the Cell Quest software.
The functional assay for multidrug resistance pumps in U937 cells was performed by using the probe rhodamine 123 as described in references 2 and 43. Briefly, cells (5 x 105 cells/ml) were stained with 0.1 µM rhodamine 123 for 15 min at 37°C in complete medium, then were centrifuged, resuspended in rhodamine-free medium, and cultured at 37°C. At the indicated time points, 5 x 105 cells were analyzed by flow cytometry.
Preparation of mitochondria and measurement of the membrane potential. Mouse liver mitochondria from male BALB/c mice (6 to 8 weeks old) were isolated by standard centrifugation techniques. All of the steps were carried out at 4°C. Briefly, mouse livers, placed in ice-cold homogenization solution (250 mM sucrose, 1 mM EGTA, 5 mM Tris-HEPES, pH 7.4), were chopped into small pieces and transferred to a precooled glass Potter-Elvejhem homogenizer containing cold homogenization medium. After homogenization, the suspension was filtered through two gauze layers and centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was centrifuged at 10,000 x g for 10 min at 4°C, and the mitochondrial pellet was resuspended in homogenization solution, centrifuged once more, and finally resuspended in 1 ml of suspension buffer (250 mM sucrose, 0.1% fatty acid-free bovine serum albumin [BSA], 5 mM Tris-HEPES, pH 7.4) and kept on ice. The mitochondrial protein was determined by means of the Bradford reagent.
To evaluate 
m changes, mitochondria were added at a final concentration of 0.1 mg/ml to the assay buffer (250 mM sucrose, 5 mM Tris-HEPES [pH 7.4], 0.1% BSA, 5 mM MgCl2, 2 mM KPi, and 5 µM safranin O), and fluorescence changes were measured with a Perkin-Elmer spectrofluorimeter (model LS 50 B). The excitation and emission wavelengths were 495 and 586 nm, respectively, with a 10-nm slit width for both emission and excitation (42). Unless otherwise specified, incubations were carried out at 25°C in the presence of 5 mM succinate as the respiratory substrate. When indicated, 100 µM EGTA was added to the suspension and to the assay buffers to ensure chelation of contaminant Ca2+. CsA was dissolved in ethanol and added to the mitochondria 5 min prior to the addition of other reagents.
The Ca2+ concentrations in the assay and suspension buffers containing mitochondria were 100 to 700 nM, as estimated with the Ca2+ calibration buffer kit (Molecular Probes) based on the relationship of Ca2+ levels to the fura-2 fluorescence intensity ratios at 340 and 380 nm.
Calcein release from mitochondria and intact cells. Mitochondria isolated from mouse livers were incubated at 25°C for 30 min in suspension buffer containing 2 µM calcein AM and then washed and resuspended in the same buffer (31). To assess calcein release, mitochondria (0.1 mg/ml) were added to the assay buffer (250 mM sucrose, 0.1% BSA, 10 µM CoCl2, 5 mM Tris-HEPES, pH 7.4) and fluorescence variations were measured with the spectrofluorimeter. The excitation and emission wavelengths were 488 and 515 nm, respectively, with a 5-nm slit width for both emission and excitation. Note that the assay buffer contained 10 µM CoCl2 to quench the fluorescence of calcein released from mitochondria.
To investigate mitochondrial permeabilization to calcein in intact cells (31), U937 cells were incubated at 37°C for 15 min in Hanks' buffered salt solution with 2 µM calcein-AM and 0.5 mM CoCl2, then washed with PBS, and resuspended in PBS-5 mM glucose supplemented with 3 µM BMAP-28 for 10 min at 37°C in the dark. When indicated, after the incubation with calcein-AM, the cells were washed and treated with 10 µM CsA for 40 min at 37°C and then incubated with the peptide. To verify that calcein localized to the mitochondria, calcein loading of the cells was followed by exposure to 0.1 µM tetramethyl-rhodamine methyl ester (TMRM) and the cells were examined with a Zeiss axioplan 2 epifluorescence microscope equipped with a photocamera and an image analyzer with the following filter settings: calcein, 450 to 490 nm excitation and 515 to 565 nm emission; and TMRM, 546 ± 12 nm excitation and 590 nm emission (31). The cells showing an intact morphology, as assessed by inspection under visible light in phase contrast, were examined under the xenon light source to detect green and red fluorescence. The emissions were collected simultaneously, resulting in a green-orange punctate fluorescence. The green and red components of the images were then analyzed separately (see Fig. 7). Calcein-AM-loaded cells were also analyzed with the cytofluorimeter, gating out dead cells and debris as described above.
|
) for each channel: (SD/
)red/(SD/
)green. A punctate (i.e., mitochondrial) distribution results in a higher SD, while normalization allows correction for different fluorescence intensities in the two channels. A localization index of 1 indicates that cytochrome c and the bc1 complex have the same distribution, which is expected in normal cells, while an index lower than 1 means that the distribution of cytochrome c is more homogeneous than that of the bc1 complex. For further details, see reference 30. Analysis of DNA fragmentation. To assess nuclear degradation, after 15 min of treatment with BMAP-28, U937 cells were incubated in peptide-free culture medium for 18 h. DNA fragmentation was analyzed at 6 and 18 h by agarose gel electrophoresis as described in reference 34. Briefly, cells were lysed with 0.5% Sarkosyl in 50 mM Tris-HCl and 10 mM EDTA (pH 8.0) in the presence of 0.5 mg of proteinase K/ml. After 1 h of incubation at 50°C, RNase A (0.15 mg/ml) was added to each sample. The lysates were analyzed by electrophoresis on 1.2% agarose gels containing 0.5 µg of ethidium bromide/ml.
| RESULTS |
|---|
|
|
|---|

m) caused by BMAP-28, we used the U937 cell line, which proved to be one of the most susceptible targets of peptide cytotoxicity (34). U937 cells were loaded with the potentiometric probe JC-1, and changes of 
m were evaluated by the shift from the red and green to green fluorescence emission after treatment with 3 µM BMAP-28 for 15 min. The short time of incubation with the peptide enabled us to analyze a cell population where the majority of the cells (65 to 75%, compared to untreated cells) were viable, as shown by the parallel analysis of physical parameters and determination of propidium iodide uptake. The results illustrated in Fig. 1, upper panel, show that cells treated with the fibronectin peptide CS-5 (used here as a negative control) were positive for both red (FL2) and green (FL1) fluorescence (Fig. 1, plot A) while a remarkable decline in the red fluorescence was observed after a 15-min incubation with 3 µM BMAP-28 (Fig. 1, plot B). No fluorescence variation was detectable when 3 µM BMAP-28(1-18), the analogue peptide lacking the hydrophobic sequence (residues 19 to 27), was used (Fig. 1, plot C) while the expected, dramatic decrease of FL2 fluorescent cells followed the treatment with the protonophore FCCP, used as a positive control (Fig. 1, plot D). Similar results were obtained when K562 cells were used as the target cells (Fig. 1, lower panel). We extended our analysis to normal human lymphocytes, which become sensitive to microbicidal doses of BMAP-28 upon in vitro activation (34). After activation by PHA-P and hrIL-2 for 8 days, the lymphoblasts were loaded with JC-1 and treated with CS-5, BMAP-28, or FCCP as described above for U937 cells. As shown in Fig. 1, lower panel, BMAP-28 and FCCP induced a decrease in the percentage of red fluorescent cells. Taken together, these data indicate that BMAP-28 induces an early decrease of mitochondrial membrane potential in both transformed and normal cells and that this event precedes cell death (see below).
|
|
Effects of BMAP-28 on isolated mitochondria.
To evaluate whether BMAP-28 affected mitochondrial function directly, 
m variations were followed as fluorescence changes of mitochondrial suspensions in the presence of safranin O. The addition of succinate caused a fast quenching of probe fluorescence, due to safranin O uptake by the mitochondria (46). The probe was released by the addition of BMAP-28, and the release rate increased with the concentration of the peptide (Fig. 3, upper panel). It should be noted that the effect was obtained at peptide concentrations between 0.25 and 0.5 µM (2.5 to 5 nmol of mitochondrial protein/mg), which are significantly lower than those required to observe a cytotoxic response (3 to 6 µM) (34). At concentrations of 2 to 3 µM, the peptide caused complete dissipation of 
m within a few seconds (Fig. 3, upper panel). BMAP-28(1-18), the truncated analogue, proved to be ineffective at concentrations up to 1 µM (Fig. 3, lower panel), and even with higher peptide concentrations, depolarization was only partial (Fig. 3, lower panel).
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
To test this point, we have studied the effects of BMAP-28 on mitochondrial permeability and energy coupling in both isolated mitochondria and intact cells. We have established that, besides plasma membrane permeabilization, BMAP-28 depolarizes mitochondria in situ, suggesting that mitochondrial dysfunction is the cause rather than the consequence of cell death and that mitochondrial depolarization is caused by opening of the PTP, as shown by its inhibition by CsA and potentiation by Ca2+. Although the peptide mediates extracellular Ca2+ influx into the cells (34), mitochondrial depolarization was induced by BMAP-28 even without the synergistic effect of Ca2+ (Fig. 2), suggesting that the intracellular Ca2+ rise may not be the primary, or the only, cause of the 
m decrease. We would like to stress that these effects were observed in three BMAP-28-sensitive cell types (two tumor cell lines and activated normal lymphocytes), suggesting that this mitochondrial mechanism of cytotoxicity may be of general significance.
The effects of BMAP-28 on mitochondria in situ. Analysis of mitochondrial function in situ with fluorescent probes is not trivial, and a key issue is the interpretation of the observed fluorescence changes. We stress that in the present work we have carefully considered and experimentally ruled out the major potential sources of artifacts and misinterpretations. The four most troublesome aspects are the following. (i) Depending on the probe and its concentration, mitochondrial depolarization may be accompanied by a fluorescence decrease or increase (27), due to the variable contribution of fluorescence quenching by mitochondrial accumulation, which would subtract from the total cellular signal. We have found that in our experimental conditions the direction of the fluorescence change induced by BMAP-28 is the same as that of the protonophore FCCP (Fig. 1), whose depolarizing effects on mitochondria have been thoroughly characterized. This in turn allows us to conclude that the decrease of the red JC-1 fluorescence is indeed due to a mitochondrial depolarization, which is in line with previous observations (9, 12).
(ii) A second problem is that potentiometric probes are substrates of the multidrug resistance P glycoprotein, which like the PTP can be inhibited by CsA (6, 7). In accord with the literature (2), we have found that the multidrug-resistant P glycoprotein has a negligible activity in the U937 batch of cells that we are using, as shown by experiments with rhodamine 123 release. These results indicate that the effects of CsA on the JC-1 fluorescence changes induced by BMAP-28 are indeed due to PTP inhibition.
(iii) A third problem is that mitochondrial probe accumulation may be affected by variations of the plasma membrane potential (6, 7, 27). Although we have not formally investigated this possibility, which is remote with the slowly redistributing JC-1, we are confident that the changes that we observe are of mitochondrial origin because they are inhibited by CsA. Furthermore, independent evidence that BMAP-28 causes PTP opening was obtained from the experiments with trapped calcein, which does not undergo membrane potential-dependent redistribution and therefore is not affected by changes of the plasma membrane potential.
(iv) Finally, mitochondrial depolarization may represent the physiological response of healthy mitochondria to an increased energy demand rather than a sign of mitochondrial dysfunction (6, 7). This is not the case for BMAP-28-dependent mitochondrial depolarization because this was prevented by the PTP inhibitor CsA but not by the F1F0 inhibitor oligomycin (not shown).
Thus, taken together our results conclusively demonstrate that BMAP-28 induces PTP opening in situ and suggest that this is due to a modulation of the PTP open time by the peptide. As discussed more in detail below, however, whether the in situ effects of BMAP-28 on the PTP are direct or indirect remains an open question.
Interactions of BMAP-28 with mitochondria and cells. We have documented that in isolated mouse liver mitochondria a CsA-sensitive mitochondrial permeability transition is caused by relatively low concentrations (below 1 µM) of BMAP-28 but not of the truncated BMAP-28(1-18). At higher concentrations (above 2 µM), the onset of mitochondrial permeabilization is faster while the sensitivity to CsA tends to disappear. This finding may suggest that at higher concentrations the peptide causes direct membrane permeabilization, which is consistent with a low but measurable permeabilizing activity of the truncated BMAP-28(1-18) peptide in isolated mitochondria. Yet, two very important points must be borne in mind. (i) With most PTP inducers, the sensitivity to CsA tends to disappear as the inducer concentration is raised (4); it is thus likely that the permeabilizing effects of BMAP-28 in the near-micromolar (cytotoxic) range are largely if not exclusively due to PTP opening rather than to a detergent-like effect. (ii) Although a permeability transition is detected in mitochondrial suspensions treated with peptide concentrations below 1 µM, i.e., lower than the cytotoxic concentration, it is reasonable to assume that only a fraction of the peptide added to the cell suspension may gain access to the mitochondrial inner membrane. In any case, these results document that the mitochondrion is a functional target of the cytotoxic effect of BMAP-28. This may be either due to peptide targeting to the mitochondrial inner membrane, possibly through its hydrophobic C-terminal sequence, or to indirect effects, e.g., on intracellular Ca2+ homeostasis or on other yet unidentified signaling pathways to the mitochondrion. Although we currently have no elements to favor either hypothesis, we note that they are not mutually exclusive and may well reinforce one another. While the signaling role of Ca2+ to the PTP is out of the question, it is also true that more than one stimulus is often needed to tip the balance of the pore open-closed transitions towards the open state (6, 7).
Mechanism of BMAP-28 cytotoxicity. The early effects of BMAP-28 on mitochondria (mitochondrial depolarization due to PTP opening and cytochrome c release) suggest that these events are determinants of BMAP-28 toxicity. Release of cytochrome c from mitochondria in situ is consistent with a permeability change caused by BMAP-28 and suggests a mechanistic link with the lethal effect of the peptide in intact cells. This is also consistent with DNA fragmentation, which could be observed in cells pulsed with BMAP-28 for 15 min and then incubated in peptide-free culture medium. It should be stressed, however, that these experiments do not prove that cytochrome c release is occurring in the same cells undergoing DNA degradation, an issue that can only be addressed when the response takes place in the whole cell population. Whether the DNA degradation is due to direct endonuclease activation through release of apoptosis-inducing factor (19, 38), to caspases activated by release of cytochrome c and possibly Smac-Diablo (13, 41), or to yet different mechanisms remains matter for future investigation. Our results should not be taken to imply that mitochondrial permeabilization through a permeability transition is the only mechanism through which BMAP-28 affects cell function. Indeed, BMAP-28 interaction with the plasma membrane causes an early rise of cytoplasmic Ca2+ (34), which may be an important additional factor generating intracellular signals that synergize with PTP opening in causing cell death.
| ACKNOWLEDGMENTS |
|---|
We are grateful to Marina Giunta (Istituto di Genetica, Policlinico Universitario di Udine) for assistance with epifluorescence microscopy.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Bailly, J. D., C. Muller, J. P. Jaffrezou, C. Demur, G. Gassar, C. Bordier, and G. Laurent. 1995. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9:799-807.[Medline]
3.
Bernardi, P., S. Vassanelli, P. Veronese, R. Colonna, I. Szabo, and M. Zoratti. 1992. Modulation of the mitochondrial permeability transition pore. Effects of protons and divalent cations. J. Biol. Chem. 267:2934-2939.
4.
Bernardi, P. 1999. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol. Rev. 79:1127-1155.
5. Bernardi, P. 1992. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. Evidence that the pore can be opened by membrane depolarization. J. Biol. Chem. 267:8334-8339.
6. Bernardi, P., V. Petronilli, F. Di Lisa, and M. Forte. 2001. A mitochondrial perspective on cell death. Trends Biochem. Sci. 26:112-117.[CrossRef][Medline]
7. Bernardi, P., L. Scorrano, R. Colonna, V. Petronilli, and F. Di Lisa. 1999. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur. J. Biochem. 264:687-701.[Medline]
8.
Brenner, G., and G. Kroemer. 2000. Apoptosis. Mitochondriathe death signal integrators. Science 289:1150-1151.
9. Cossarizza, A., M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi. 1993. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 197:40-45.[CrossRef][Medline]
10. Crompton, M. 2000. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr. Opin. Cell Biol. 12:414-419.[CrossRef][Medline]
11. Diaz-Achirica, P., S. Prieto, J. Ubach, D. Andreu, E. Rial, and L. Rivas. 1994. Permeabilization of the mitochondrial inner membrane by short cecropin-A-melittin hybrid peptides. Eur. J. Biochem. 224:257-263.[Medline]
12. Di Lisa, F., P. S. Blank, R. Colonna, G. Gambassi, H. S. Silverman, M. D. Stern, and R. G. Hansford. 1995. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J. Physiol. (London) 486:1-13.
13. Du, C., M. Fang, Y. Li, L. Li, and X. Wang. 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42.[CrossRef][Medline]
14.
Gallo, R., M. Ono, T. Povsic, C. Page, E. Eriksson, M. Klagsbrun, and M. Bernfield. 1994. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA 91:11035-11039.
15.
Green, D. R., and J. C. Reed. 1998. Mitochondria and apoptosis. Science 281:1309-1312.
16.
Helmerhorst, E. J., P. Breeuwer, W. van't Hof, E. Walgreen-Weterings, L. C. Oomen, E. Veerman, A. Amerongen, and T. Abee. 1999. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J. Biol. Chem. 274:7286-7291.
17. Huang, H., C. R. Ross, and F. Blecha. 1997. Chemoattractant properties of PR39, a neutrophil antibacterial peptide. J. Leukoc. Biol. 61:624-629.[Abstract]
18. Hugosson, M., D. Andreu, H. G. Boman, and E. Glaser. 1994. Antibacterial peptides and mitochondrial presequences affect mitochondrial coupling, respiration and protein import. Eur. J. Biochem. 223:1027-1033.[Medline]
19. Joza, N., S. A. Susin, E. Daugas, W. L. Stanford, S. K. Cho, C. Y. Li, T. Sasaki, A. J. Elia, H. Y. Cheng, L. Ravagnan, K. F. Ferri, N. Zamzami, A. Wakeham, R. Hakem, H. Yoshida, Y. Y. Kong, T. W. Mak, J. C. Zuniga-Pflucker, G. Kroemer, and J. M. Penninger. 2001. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410:549-552.[CrossRef][Medline]
20.
Krajewski, S., M. Krajewska, L. M. Ellerby, K. Welsh, Z. Xie, Q. L. Deveraux, G. S. Salvesen, D. E. Bredesen, R. E. Rosenthal, G. Fiskum, and J. C. Reed. 1999. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc. Natl. Acad. Sci. USA 96:5752-5757.
21. Kroemer, G., B. Dallaporta, and M. Resche-Rigon. 1998. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 60:619-642.[CrossRef][Medline]
22. Lehrer, R. I., A. K. Lichtenstein, and T. Ganz. 1993. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 11:105-128.[CrossRef][Medline]
23. Lemasters, J. J., T. Qian, C. A. Bradham, D. A. Brenner, W. E. Cascio, L. C. Trost, Y. Nishimura, A. L. Nieminen, and B. Herman. 1999. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J. Bioenerg. Biomembr. 31:305-319.[CrossRef][Medline]
24. Lencer, W. I., G. Cheung, G. R. Strohmeier, M. G. Currie, A. J. Ouellette, M. E. Selsted, and J. L. Madara. 1997. Induction of epithelial chloride secretion by channel-forming cryptidins 2 and 3. Proc. Natl. Acad. Sci. USA 94:8585-8589.
25. Lichtenstein, A. 1991. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J. Clin. Investig. 88:93-100.
26. Lichtenstein, A. K., T. Ganz, T. Nguyen, M. Selsted, and R. I. Lehrer. 1988. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J. Immunol. 140:2686-2694.[Abstract]
27. Nicholls, D. G., and M. W. Ward. 2000. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci. 23:166-174.[CrossRef][Medline]
28.
Nicolli, A., E. Basso, V. Petronilli, R. M. Wenger, and P. Bernardi. 1996. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J. Biol. Chem. 271:2185-2192.
29.
Ohsaki, Y., A. F. Gazdar, H. C. Chen, and B. Johnson. 1992. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 52:3534-3538.
30.
Petronilli, V., D. Penzo, L. Scorrano, P. Bernardi, and F. Di Lisa. 2000. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J. Biol. Chem. 276:12030-12034.
31.
Petronilli, V., G. Miotto, M. Canton, M. Brini, R. Colonna, P. Bernardi, and F. Di Lisa. 1999. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys. J. 76:725-734.
32.
Pfeiffer, D., T. I. Gudz, S. A. Novgorodov, and W. Erdhal. 1994. The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition. J. Biol. Chem. 270:4923-4932.
33.
Risso, A. 2000. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J. Leukoc. Biol. 68:785-792.
34. Risso, A., M. Zanetti, and R. Gennaro. 1998. Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell. Immunol. 189:107-115.[CrossRef][Medline]
35. Shimizu, S., M. Narita, and Y. Tsujimoto. 1999. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399:483-487.[CrossRef][Medline]
36.
Skerlavaj, B., R. Gennaro, L. Bagella, L. Merluzzi, A. Risso, and M. Zanetti. 1996. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J. Biol. Chem. 271:28375-28381.
37.
Susin, S. A., H. K. Lorenzo, N. Zamzami, I. Marzo, K. Brenner, N. Larochette, M. C. Prevost, P. M. Alzari, and G. Kroemer. 1999. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189:381-394.
38. Susin, S. A., H. K. Lorenzo, N. Zamzami, I. Marzo, B. E. Snow, G. M. Brothers, J. Mangion, E. Jacotot, P. Costantini, M. Loeffler, N. Larochette, D. R.Goodlett, R. Aebersold, D. P. Siderovski, J. M. Penninger, and G. Kroemer. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441-446.[CrossRef][Medline]
39.
Susin, S. A., N. Zamzami, M. Castedo, E. Daugas, H. G. Wang, S. Geley, F. Fassy, J. Reed, and G. Kroemer. 1997. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J. Exp. Med. 186:25-37.
40.
Vande Velde, C., J. Cizeau, D. Dubik, J. Alimonti, T. Brown, S. Israels, R. Hakem, and A. H. Greenberg. 2000. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell. Biol. 20:5454-5468.
41. Verhagen, A. M., G. Ekert, M. Pakusch, J. Silke, L. M. Connolly, G. E. Reid, R. L. Moritz, R. J. Simpson, and D. L. Vaux. 2000. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43-53.[CrossRef][Medline]
42. Vianello, A., F. Macrì, E. Braidot, and E. N. Mokhova. 1995. Effect of 6-ketocholestanol on FCCP- and DNP-induced uncoupling in plant mitochondria. FEBS Lett. 365:7-9.[CrossRef][Medline]
43. Weaver, J. L., P. S. Pine, A. Aszalos, P. V. Schoenlein, S. J. Currier, R. Padmanabhan, and M. M. Gottesman. 1991. Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells. Exp. Cell Res. 196:323-329.[CrossRef][Medline]
44.
Yang, D., O. Chertov, S. N. Bykovskaia, Q. Chen, M. J. Buffo, J. Shogan, M. Anderson, J. M. Schroeder, J. M. Wang, O. M. Z. Howard, and J. J. Oppenheim. 1999. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525-528.
45. Zanetti, M., R. Gennaro, and D. Romeo. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374:1-5.[CrossRef][Medline]
46. Zanotti, A., and G. F. Azzone. 1980. Safranin as membrane potential probe in rat liver mitochondria. Arch. Biochem. Biophys. 201:255-265.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. V |
|---|